معرفی
Chrishan Samuel is a Professor and Head of the Fibrosis Laboratory in the Department of Pharmacology at Monash University. He holds a position as a Monash Biomedicine Discovery Fellow. His research focuses on identifying novel therapeutic targets for fibrosis prevention in cardiovascular, renal, and allergic airways diseases, with a primary interest in the anti-fibrotic potential of relaxin and other anti-fibrotic agents. Samuel leads projects investigating combination therapies for tissue repair and collaborates on studies involving nanoparticle drug delivery and placental inflammation in preeclampsia.
Samuel's expertise aligns with UN Sustainable Development Goals related to good health and well-being. His work spans collaborations across multiple institutions, including the Victorian Heart Institute. Key research areas include fibrosis mechanisms, stem cell biology, and translational therapies. Recent projects include developing engineered mesenchymal stromal cells for chronic kidney disease and evaluating nanoparticle toxicity in drug delivery systems.
His research output includes peer-reviewed articles on topics such as angiotensin receptor crosstalk, Wnt/β-catenin signaling, and relaxin's role in cardiac fibrosis. He actively engages in grants and partnerships, exemplified by projects funded by Aus Bio Limited and Ferring Innovation Grants. Samuel's lab explores cutting-edge methods like second-harmonic generation imaging for fibrosis assessment and combines cell therapies with anti-fibrotic drugs for enhanced efficacy.
